{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:05:12Z","timestamp":1794701112650,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0265-7","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:12:30Z","timestamp":1496736750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, \u03b1-synuclein, and total tau in combination with A\u03b2(1\u201342)\/A\u03b2(1\u201340)"],"prefix":"10.1186","volume":"9","author":[{"given":"Hugo","family":"Vanderstichele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leentje","family":"Demeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Coart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Mauroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"265_CR1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"265_CR2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131\u201344.","journal-title":"Nat Rev Neurol"},{"key":"265_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"265_CR4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert M-O, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol"},{"key":"265_CR5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging\u2014FDA approval of Florbetapir F18 injection. N Engl J Med. 2012;367:885\u20137.","journal-title":"N Engl J Med"},{"key":"265_CR6","volume-title":"Qualification opinion of Alzheimer\u2019s disease novel methodologies\/biomarkers for BMS-708163","author":"European Medicines Agency","year":"2011","unstructured":"European Medicines Agency. Qualification opinion of Alzheimer\u2019s disease novel methodologies\/biomarkers for BMS-708163. 2011. http:\/\/www.ema.europa.eu\/docs\/en GB\/document library\/Regulatory and procedural guideline\/2011\/02\/WC500102018.pdf."},{"key":"265_CR7","unstructured":"US Food and Drug Administration. Drug Development Tools (DDT) letters of support. \nhttp:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/ucm434382.htm"},{"key":"265_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65\u201373.","journal-title":"Alzheimers Dement"},{"key":"265_CR9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M Campo del","year":"2012","unstructured":"del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehman S, Molinuevo JL, Parnetti L, Perret-Liaudet A, S\u00e1ez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C. Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419\u201330.","journal-title":"Biomark Med"},{"key":"265_CR10","doi-asserted-by":"publisher","unstructured":"Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K; IFCC Working Group on Standardization of CSF proteins (WG-CSF). CSF A\u03b21-42\u2014an excellent but complicated Alzheimer\u2019s biomarker\u2014a route to standardisation. Clin Chim Acta 2016. doi:\n10.1016\/j.cca.2016.05.014\n\n.","DOI":"10.1016\/j.cca.2016.05.014"},{"key":"265_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund Jr RE, Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K. Technical performance of a novel, fully automated electrochemiluminescence immuno-assay for the quantitation of \u03b2-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12:517\u201326.","journal-title":"Alzheimers Dement"},{"key":"265_CR12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K. Swedish BioFINDER study group, Hansson O. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"key":"265_CR13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2016","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2016;55:813\u201322.","journal-title":"J Alzheimers Dis"},{"key":"265_CR14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K. Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42\/A\u03b21-40 ratio\u2014a cross-validation study against amyloid PET. J Neurochem. 2016;139:651\u20138.","journal-title":"J Neurochem"},{"key":"265_CR15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3233\/JAD-160286","volume":"53","author":"HMJ Vanderstichele","year":"2016","unstructured":"Vanderstichele HMJ, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, Mauroo K, Brix B, Hansson O. Optimized standard operating procedures for the analysis of cerebrospinal fluid A\u03b242 and the ratios of A\u03b2 isoforms using low protein binding tubes. J Alzheimers Dis. 2016;53:1121\u201332.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"265_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TLS, Stoops EEJ, Vanderstichele HMJ, Brix B, Darby HD, Vandijck MLJ, Ladenson JH, Morris JC, Holtzman DM, Fagan AM. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015;72(9):1029\u201342. doi:\n10.1001\/jamaneurol.2015.1285\n\n.","journal-title":"JAMA Neurol"},{"key":"265_CR17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1515\/cclm-2015-0733","volume":"54","author":"M Bjerke","year":"2016","unstructured":"Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, Blennow K. Assessing the commutability of reference material formats for the harmonization of amyloid-\u03b2 measurements. Clin Chem Lab Med. 2016;54:1177\u201391.","journal-title":"Clin Chem Lab Med"},{"key":"265_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/JAD-150883","volume":"52","author":"N Lelental","year":"2016","unstructured":"Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C, Mollenhauer B, Parnetti L, Chiasserini D, Molinuevo JL, Perret-Liaudet A, Verbeek MM, Andreasen N, Brosseron F, Bahl JM, Herukka S-K, Hausner L, Fr\u00f6lich L, Labonte A, Poirier J, Miller A-M, Zilka N, Kovacech B, Urbani A, Suardi S, Oliveira C, Baldeiras I, Dubois B, Rot U, Lehmann S, Skinningsrud A, Betsou F, Wiltfang J, Gkatzima O, Winblad B, Buchfelder M, Kornhuber J, Lewczuk P. Comparison of different matrices as potential quality control samples for neurochemical dementia diagnostics. J Alzheimers Dis. 2016;52:51\u201364.","journal-title":"J Alzheimers Dis"},{"key":"265_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-150953","volume":"51","author":"E Niemantsverdriet","year":"2016","unstructured":"Niemantsverdriet E, Goossens J, Struyfs H, Martin J-J, Goeman J, De Deyn PP, Vanderstichele H, Engelborghs S. Diagnostic impact of cerebrospinal fluid biomarker (pre-) analytical variability in Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51:97\u2013106.","journal-title":"J Alzheimers Dis"},{"key":"265_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JAD-150511","volume":"49","author":"LG Barrado","year":"2016","unstructured":"Barrado LG, Coart E, Vanderstichele HMJ, Burzykowski T. Transferring cut-off values between assays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers. J Alzheimers Dis. 2016;49:187\u201399.","journal-title":"J Alzheimers Dis"},{"key":"265_CR21","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.neurobiolaging.2015.05.003","volume":"36","author":"N Kruse","year":"2015","unstructured":"Kruse N, Persson S, Alcolea D, Bahl JMC, Baldeiras I, Capello E, Chiasserini D, Chiavetto LB, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, Garc\u00eda-Ayll\u00f3n M-S, Genc S, Gkatzima O, Heegaard NHH, Janeiro AM, Kov\u00e1\u010dech B, Kuiperij HB, Leit\u00e3o MJ, Lle\u00f3 A, Martins M, Matos M, Mollergard HM, Nobili F, \u00d6hrfelt A, Parnetti L, de Oliveira CR, Rot U, S\u00e1ez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging. 2015;36:2587\u201396.","journal-title":"Neurobiol Aging"},{"key":"265_CR22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2015.08.003","volume":"426","author":"N Kruse","year":"2015","unstructured":"Kruse N, Mollenhauer B. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human \u03b1-synuclein in cerebrospinal fluid. J Immunol Methods. 2015;426:70\u20135.","journal-title":"J Immunol Methods"},{"key":"265_CR23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","volume":"68","author":"SW Scheff","year":"2007","unstructured":"Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501\u20138.","journal-title":"Neurology"},{"key":"265_CR24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","volume":"20","author":"P Davidsson","year":"1999","unstructured":"Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999;20:431\u20137.","journal-title":"Electrophoresis"},{"key":"265_CR25","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3233\/JAD-160227","volume":"53","author":"A Vos De","year":"2016","unstructured":"De Vos A, Struyfs H, Jacobs D, Fransen E, Klewansky T, De Roeck E, Robberecht C, Van Broeckhoven C, Duyckaerts C, Engelborghs S, Vanmechelen E. The cerebrospinal fluid neurogranin\/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer\u2019s disease. J Alzheimers Dis. 2016;53:1523\u201338.","journal-title":"J Alzheimers Dis"},{"key":"265_CR26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275\u201380.","journal-title":"JAMA Neurol"},{"issue":"1","key":"265_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40.","journal-title":"Alzheimers Res Ther"},{"key":"265_CR28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","volume":"9","author":"L Parnetti","year":"2013","unstructured":"Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013;9:131\u201340.","journal-title":"Nat Rev Neurol"},{"key":"265_CR29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5:55\u20139.","journal-title":"Neurodegener Dis"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0265-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T08:12:49Z","timestamp":1496736769000},"score":1,"resource":{"primary":{"URL":"http:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0265-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0265-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]},"article-number":"40"}}